ART27.13

Three clinical programs, one core molecule, and a capital-efficient strategy position Artelo Biosciences for sustained growth beyond a single indication BRISTOL, Tenn., March 25, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) is drawing increased attention following its expansion into the $16.3 billion glaucoma market through a fully funded investigator-sponsored clinical study—an announcement that underscores a broader story: a multi-platform biotech pipeline built for durability across several high-value therapeutic areas. Artelo Biosciences is running three distinct clinical-stage programs — in oncology support, neuropathic pain, and CNS disorders — while simultaneously expanding its lead compound into ophthalmology through fully externally funded studies. This isn't a one-trick biotech. It's a platform play in one of medicine's most underserved mechanistic categories. The Case for ARTL in One Paragraph Most coverage of Artelo Biosciences has focused on the glaucoma announcement — a meaningful and capital-efficient pipeline expansion that is genuinely worth tracking. But investors who stop there are missing the larger thesis. Artelo has successfully advanced three separate compounds through human clinical trials, generated positive interim Phase 2 data, attracted academic partners across the UK and Ireland, earned European patent protection extending to 2041, received regulatory guidance from the UK’s MHRA, and drawn unsolicited partnership inquiries from global pharmaceutical companies — all while operating with a lean structure that keeps burn focused on science rather than overhead. This report goes deeper than the glaucoma headline. We examine all three pipeline assets, the regulatory tailwinds reshaping the cannabinoid therapeutic landscape, the intellectual property architecture that protects the franchise, and the strategic signals embedded in recent SEC filings and press releases. The Pipeline: Three Compounds, One Scientific Thesis Artelo’s pipeline is built around a single mechanistic conviction: that modulating lipid-signaling pathways — including the endocannabinoid system — can produce clinically meaningful therapeutic outcomes across multiple disease areas without the CNS liability that has historically limited cannabinoid-based drug development. That conviction is now backed by human data across all three programs. ART27.13 — The Lead Asset with Multiple Shots on Goal ART27.13 did not originate at Artelo. It was initially developed by AstraZeneca — a meaningful credential that speaks to the compound’s pharmaceutical-grade pedigree. By the time Artelo licensed it, ART27.13 had already been evaluated in seven clinical studies involving more than 280 participants. Artelo’s contribution has been to identify the therapeutic sweet spot: peripheral selectivity that delivers systemic metabolic benefit while sidestepping the CNS effects that made first-generation cannabinoids clinically impractical. These are not modest improvements. In cancer anorexia cachexia — where there is no FDA-approved treatment — a 6.4% weight gain versus a 5.4% weight loss in the placebo arm represents a clinically meaningful signal. The Phase 2 data was presented at the 17th International Conference on Sarcopenia, Cachexia & Wasting Disorders by Professor Barry J.A. Laird of Edinburgh Cancer Centre — giving the data independent scientific credibility beyond the company’s own disclosures. The glaucoma expansion layered on top of this is not speculative pivoting. It is a second indication discovered organically through the mechanism: ART27.13’s CB2 receptor activity offers both intraocular pressure modulation and neuroprotective properties that current glaucoma therapies don’t address. The investigator-sponsored trial structure means Artelo advances this indication at zero direct cost to shareholders while retaining full data rights. “This collaboration broadens ART27.13’s therapeutic profile beyond cancer-related anorexia while preserving our internal focus on the lead indication.” — Gregory D. Gorgas, President & CEO, Artelo Biosciences ART26.12 — The Hidden Gem in a $20 Billion Pain Category If ART27.13 is the headline act, ART26.12 may be the most underappreciated asset in the portfolio. Artelo’s FABP5 (Fatty Acid Binding Protein 5) inhibitor completed its first-in-human Phase 1 single-ascending-dose study in 2025 with results that de-risked the program substantially. The human data showed no serious adverse events, a favorable safety profile across all dose levels tested up to 1,050 mg, predictable and linear pharmacokinetics, and dosing flexibility in both fed and fasted states. These are the precise attributes a pharmaceutical partner wants to see before committing capital to a Phase 2 collaboration. What makes ART26.12 strategically significant is what the preclinical data demonstrates beyond the Phase 1 safety signal. In an osteoarthritis pain model, ART26.12 produced sustained analgesic effects without the development of tolerance — a crucial differentiator from opioids and a meaningful advantage over NSAIDs like naproxen, which it matched in efficacy. A separate publication showed antidepressant-like activity on par with sertraline (Zoloft®) with improved cognitive benefits in preclinical models. The lead indication under an active FDA IND is chemotherapy-induced peripheral neuropathy — a condition affecting a substantial share of the cancer patient population, currently managed with a limited toolkit of off-label medications. Multiple ascending dose enrollment is being prepared for Q3 2026. FABP inhibitors represent a nascent but rapidly growing pharmacological category. Artelo holds an extensive library of small molecule FABP inhibitors with demonstrated preclinical promise across cancers, neuropathic pain, psoriasis, and anxiety. ART26.12 is the beachhead, not the ceiling, of this franchise. ART12.11 — A Proprietary CBD Reinvention with Regulatory Momentum ART12.11 is Artelo’s wholly owned CBD/tetramethylpyrazine cocrystal — a novel crystalline form of cannabidiol that has demonstrated improved pharmacokinetics and efficacy versus conventional CBD in nonclinical studies. The cocrystal format is not a marketing distinction; it is a chemistry distinction that produces measurably different bioavailability and stability profiles. The compound received favorable UK MHRA regulatory guidance supporting streamlined Phase 1 development with potential accelerated pathways. First-in-human studies are planned for the first half of 2026. Preclinical data showed antidepressant-like activity on par with — and cognitive advantages over — sertraline. ART12.11 is protected by patents extending to 2038 and is positioned at the intersection of two significant tailwinds: the White House executive order expanding CBD research and the Medicare pilot program for CBD reimbursement announced in late 2025. The Regulatory Environment Has Shifted in Artelo’s Favor The cannabinoid therapeutic space has long operated under a regulatory cloud that created genuine commercial uncertainty even for companies with compelling science. That cloud is lifting — and the timing benefits Artelo directly. PRESIDENTIAL EXECUTIVE ORDER — CBD RESEARCH EXPANSION In December 2025, the White House issued an executive order expanding CBD research and access. Artelo specifically highlighted ART12.11 as a leading pharmaceutical-grade cannabidiol candidate positioned to benefit. This policy shift removes a meaningful impediment to clinical development timelines and potential reimbursement conversations with payers. MEDICARE CBD REIMBURSEMENT PILOT The White House launched a Medicare pilot program for CBD reimbursement — a first in U.S. healthcare policy. For a company with a proprietary, pharmaceutical-grade CBD cocrystal (ART12.11) and a peripheral CB1/CB2 agonist in active clinical trials, this policy shift represents a potential inflection point in addressable market size if clinical validation follows the political momentum. UK MHRA GUIDANCE — STREAMLINED PATHWAY Artelo received clear guidance from the UK’s MHRA on a streamlined pathway to the clinic for ART12.11. The UK regulatory environment has historically been more receptive to cannabinoid-adjacent therapeutics, and the MHRA’s accelerated pathway designation positions ART12.11 for faster Phase 1 execution than a U.S.-only development strategy would allow. These three policy developments — the Presidential EO, the Medicare pilot, and the MHRA pathway — arrived within months of each other. For Artelo, they represent a convergence of regulatory tailwinds that the company was already positioned to capture through a pipeline designed specifically around peripheral selectivity and pharmaceutical-grade formulation. The Market Opportunity Matrix Artelo’s total addressable market cannot be evaluated through a single-indication lens. Each of its three programs operates in a distinct therapeutic category with large and growing patient populations. The cancer anorexia cachexia opportunity deserves particular attention because it carries a differentiator that is rarely available in biotech: there is no FDA-approved pharmacological treatment for the condition. The 2020 ASCO guidelines recommend no specific pharmacological intervention as standard of care. ART27.13, if it completes Phase 2 with the signal strength suggested by interim data, would enter a market with no incumbent to displace. The Intellectual Property Fortress Patent protection is the commercial runway that converts clinical success into durable value. Artelo’s IP position provides meaningful long-dated protection across all three programs. The ART27.13 European patent allowance through December 2041 is particularly significant for licensing discussions. A potential pharmaceutical partner evaluating a collaboration would find a compound with 15+ years of commercial patent life, positive Phase 2 human data, and a clean safety profile across 7 studies — the combination that routinely drives outlicensing conversations in mid-stage biotech deals. The Partnership Signals Investors Should Not Ignore Among the most consequential disclosures in Artelo’s Q3 2025 earnings update — one that received little investor attention — was the company’s acknowledgment of unsolicited interest: Following positive Phase 2 results and coverage by UK and USA media outlets, Artelo has received multiple expressions of potential collaboration interest from global and regional pharmaceutical companies. — Artelo Biosciences Q3 2025 Business Update In the clinical-stage biotech world, unsolicited partnership inquiries at the Phase 2 stage are not routine events. They represent external validation from parties with their own development budgets and scientific advisory teams — parties who don’t make preliminary outreach calls without having reviewed the data themselves. These expressions of interest have not converted to announced deals, and there is no guarantee they will. But they establish that Artelo’s science is attracting attention beyond the retail investor community — and that the pipeline’s future may not depend solely on Artelo’s own capital position to reach commercialization. The IST model for the glaucoma study reflects the same dynamic: Professor Augusto Azuara-Blanco at Queen’s University Belfast and the Northern Ireland Clinical Trials Unit did not agree to sponsor a trial of ART27.13 without scientific conviction in the mechanism. Academic institution partnership signals and pharma collaboration inquiries, taken together, suggest that ART27.13’s clinical credibility is resonating well beyond the company’s own press releases. A Capital-Efficient Strategy Built for the Stage Artelo’s management team has made a series of deliberate structural decisions that reflect a clear-eyed understanding of how to advance a multi-program biotech pipeline while preserving shareholder capital. The result is a company that is doing more with less — and doing it strategically. The investigator-sponsored trial model, most visibly deployed for the glaucoma expansion, is the clearest expression of this philosophy. By partnering with Glaucoma UK, the HSC R&D Division, and Queen’s University Belfast, Artelo advances a $16.3 billion market opportunity without spending a dollar of shareholder capital on study costs — while retaining full data rights and strategic control. This is not a compromise; it is a competitive advantage. The company entered 2026 with a secured equity access facility of up to $25 million — expandable to $50 million — providing a meaningful capital bridge as clinical programs continue to mature and generate data. With seven employees and a 2025 operating structure that directed $5.4 million of its total spend directly into R&D, Artelo runs lean by design. The science consumes the capital, not the overhead. The 1-for-3 reverse stock split completed in March 2026 further strengthens the company’s market positioning, improving share price structure and marketability for a broadening investor audience as clinical catalysts approach across all three programs. As with all clinical-stage biopharmaceutical companies, investment in ARTL involves inherent development, regulatory, and capital risk. Investors are encouraged to review the company’s full SEC filings, including the Annual Report on Form 10-K for fiscal year 2025, for complete financial and risk information. This report does not constitute investment advice. Please see the full disclosure statement below. What distinguishes Artelo from the broader universe of early-stage biotech is the quality of the science advancing through this stage. Three programs with human data. A lead compound with 280+ clinical participants across seven studies. External institutions willing to co-fund and co-investigate. Global pharmaceutical companies making unsolicited contact. These are the markers of a pipeline that the scientific community is taking seriously — and they represent the foundation on which long-term value creation is built. Why Artelo Biosciences Warrants Continued Attention The biotech graveyard is littered with companies that had one interesting compound and ran out of money before the data arrived. Artelo is operating differently — and the structural choices it has made in the past 18 months reflect a management team that understands how to extend runway while advancing science. The investment thesis rests on several compounding factors: ◆ ART27.13's Phase 2 interim data is positive and statistically meaningful in a disease with no approved standard of care — establishing genuine first-mover potential. ◆ The glaucoma IST advances a $16.3 billion market opportunity at zero direct cost to shareholders, funded entirely by Glaucoma UK and the HSC R&D Division. ◆ ART26.12 completed a clean, well-tolerated Phase 1 and is progressing to MAD — with preclinical analgesic efficacy on par with naproxen and antidepressant activity matching Zoloft®. ◆ ART12.11, a wholly owned CBD cocrystal with superior PK, is entering Phase 1 with MHRA streamlined guidance and is aligned with the Presidential executive order expanding CBD research. ◆ Unsolicited partnership expressions from global pharmaceutical companies confirm that the science is attracting professional attention beyond the retail market. ◆ European patent protection through 2041 provides a commercial runway long enough to support licensing, partnership, or acquisition discussions from a position of structural strength. ◆ The lean operating structure keeps burn focused on clinical advancement rather than corporate overhead — seven employees, $5.4M R&D, $6.0M G&A in fiscal 2025. Artelo is structured for this stage of development — lean, externally leveraged, and advancing on multiple clinical fronts simultaneously. The $25 million equity access facility, the capital-free IST model for glaucoma, and the disciplined focus on R&D over overhead collectively reflect a management team executing with purpose. But the scientific platform underneath that fragility is not fragile. It is methodical, peer-reviewed, externally validated, and advancing on multiple fronts simultaneously. We will be watching every 2026 milestone closely. The data will tell the real story — and the conditions are in place for that story to be a good one. IMPORTANT DISCLOSURES About The Vanderbilt Report: The Vanderbilt Report (AB Holdings LLC) is an independent financial communications platform providing analysis and research on publicly traded companies, with a focus on small-cap and micro-cap equities. Compensation Disclosure: Artelo Biosciences compensated The Vanderbilt Report in connection with this publication. This report has been prepared for informational purposes only and does not constitute investment advice, a solicitation to buy or sell securities, or a recommendation of any kind. This report contains forward-looking statements based on currently available information; actual results may differ materially. Risk Warning: Investing in clinical-stage biopharmaceutical companies involves significant risk, including the possible loss of the entire investment. Clinical trials can fail. Regulatory approvals are not guaranteed. Companies discussed herein may face capital constraints, listing compliance issues, or adverse clinical outcomes. Data sourced from Artelo Biosciences SEC filings (10-K FY2025, 8-K, S-1), GlobeNewswire press releases, artelobio.com pipeline disclosures, and third-party market intelligence reports. All figures accurate as of the date of publication: March 2026. Media Contact: The Vanderbilt Report Jake Rivers media@vanderbiltreport.com Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7dc69ce5-8e3b-4b86-a8d7-367f6cf33918 https://www.globenewswire.com/NewsRoom/AttachmentNg/0bf0b3d0-048d-4b6d-9270-3f83acfd9826 https://www.globenewswire.com/NewsRoom/AttachmentNg/7297ad5f-4c84-4754-ae93-ae532d154f6a https://www.globenewswire.com/NewsRoom/AttachmentNg/32a1ebb6-12f5-43bc-9a53-584f271d4712 Released March 25, 2026

Evaluating Potential to Preserve Muscle Mass Associated with Weight Reduction Announces Preclinical Study Initiation, Patent Filing and Publication of Independent Scientific Research SOLANA BEACH, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced a strategic expansion opportunity for ART27.13 in muscle preservation for patients undergoing glucagon-like peptide-1 (“GLP-1”) receptor agonist therapy. The initiative is supported by four significant developments: observations of a muscle protective effect in the CAReS trial when ART27.13 was given to patients with cancer anorexia and cachexia (shown by improvements in lean body mass and physical activity) and in preclinical research of cancer cachexia (reversal of myotoxic effects of cancer caused by CB2 activation) conducted by Professor Richard Porter at Trinity College Dublin, Ireland; publication of independent peer-reviewed research validating the differentiated pharmacology of ART27.13 compared to other CB2 agonists and supporting its potential utility in muscle preservation; filing of a provisional patent application covering the use of cannabinoid receptor agonism to prevent or mitigate muscle loss associated with GLP-1 therapy; and initiation of a non-clinical study to evaluate ART27.13 in models relevant to GLP-1-associated muscle preservation. These positive early developments position ART27.13 as a potential companion therapy candidate for one of the most important and fastest-growing categories in biopharma. J.P. Morgan recently projected the global incretin market, which includes GLP-1 medicines, could reach $200 billion by 2030, while estimating approximately 25 million Americans could be receiving GLP-1 treatment by 2030. As use of GLP-1-based medicines continues to expand, published analyses have reported that loss of lean body mass may account for a meaningful proportion of total weight lost with GLP-1-based therapies, highlighting an unmet need for muscle preservation. “GLP-1 medicines are reshaping the treatment landscape for obesity and metabolic disease, yet preservation of muscle and lean body mass remains a critical issue for patients, physicians, and the industry,” said Dr. Andrew Yates, Senior Vice President and Chief Scientific Officer of Artelo. “We believe ART27.13 may represent a differentiated approach as a potential companion therapy in this setting. Based upon the results and analysis published in a recent independent research study, “Kinetic multiplex assay to assess biased signaling of clinical GPCR agonists”, wherein the authors described ART27.13 as a superagonist, we consider our GPCR drug candidate to have one of the most compelling pharmacologic profiles among the 17 clinically studied CB2 agonists. With new non-clinical research commencing and the recent filing of a patent application covering the use of CB2 agonists with GLP-1 drugs, we are aiming to build a scientific and strategic foundation with ART27.13 in an area of potentially significant commercial relevance.” “Our strategy is to advance ART27.13 where the biology, clinical need and commercial opportunity intersect,” said Gregory D. Gorgas, President and Chief Executive Officer of Artelo. “The rapid adoption of GLP-1 therapies has created a large and increasingly visible need for solutions that may help address treatment-associated muscle loss. We believe Artelo is moving quickly to establish an early prominent role in what could become an important adjunct category within the GLP-1 treatment landscape.” This announcement follows Artelo’s disclosure on March 18 that a third-party fully funded clinical study is planned to start in Q2 2026 to evaluate ART27.13 in Glaucoma patients, further illustrating the compound’s perceived versatility as a therapeutic treatment. About ART27.13 ART27.13 is being developed as a once-daily, orally administered, peripherally restricted cannabinoid receptor agonist initially created by AstraZeneca. Artelo is advancing ART27.13 as a potential treatment for cancer-related anorexia and cachexia as well as evaluating its potential in glaucoma, while exploring broader applications where its pharmacology may support preservation of lean body mass, activity, and quality of life. In interim CAReS data, patients treated with ART27.13 demonstrated improvements in weight, lean body mass and activity, with the highest-dose cohort showing average weight gain of approximately 6% compared with approximately 5% weight loss in placebo-treated patients. About Artelo Biosciences Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, with a diversified pipeline addressing significant unmet needs in anorexia, cancer, anxiety, dermatologic conditions, pain, inflammation, and diseases of the eye. Led by an experienced executive team collaborating with world-class researchers and technology partners, Artelo applies rigorous scientific, regulatory, and commercial, discipline to maximize stakeholder value. More information is available at www.artelobio.com and X: @ArteloBio. Forward Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including but not limited to: our ability to raise additional capital in the future; the inherent uncertainties of preclinical and clinical research, including the possibility that preclinical results may not be replicated in clinical trials; the uncertainty of patent protection and the potential for intellectual property challenges; the highly competitive nature of the pharmaceutical industry, including the GLP-1 and companion therapy markets; the risk that third-party market projections may not materialize or that the Company may not be able to participate in projected market opportunities; and the early stage of our muscle preservation research program. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws. Investor Relations Contact: Crescendo Communications, LLC Tel: 212-671-1020 Email: ARTL@crescendo-ir.com Released March 25, 2026